cotadutide

04/29/2022 - "The inclusion criteria were randomized controlled trials that assessed the safety and efficacy of Cotadutide versus placebo or any anti-diabetes drugs in patients with type 2 diabetes mellitus and a BMI between 22 kg/m2 and 40 kg/m2. "
04/29/2022 - "This study aimed to explore the safety and efficacy of Cotadutide as a treatment for type 2 diabetes individuals. "
01/01/2023 - "Safety/tolerability, efficacy and pharmacokinetics of 600-μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m2 or higher: A phase I, randomized, double-blind, placebo-controlled study."
01/01/2022 - "This study analyzed 8834 plasma concentrations of cotadutide from 759 subjects with type 2 diabetes who received daily subcutaneous doses from 20 to 600 μg from six clinical studies. "
01/01/2023 - "To assess the safety/tolerability, efficacy and pharmacokinetics of once-daily, 600-μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m2 or higher. "

01/01/2023 - "This phase I, randomized, double-blind, placebo-controlled study (NCT04208620) enrolled patients to receive subcutaneous cotadutide at an escalating dose to determine the highest tolerated clinical dose (Cohort 1), then applied in Cohort 2. The primary endpoint was safety, including treatment-emergent adverse events (TEAEs); secondary endpoints included glycaemic control and body weight. "
01/01/2022 - "Body weight-based dosing is not necessary for cotadutide based on the simulation using the final population pharmacokinetic modeling. "
01/01/2022 - "The impact of covariates on cotadutide pharmacokinetics was quantified, and body weight effect on cotadutide exposure was further evaluated using a simulation approach. "
01/01/2021 - "Cotadutide significantly decreased HbA1c and body weight at weeks 14 and 54 versus placebo (all P < 0.001). "
01/01/2020 - "Cotadutide, a GLP-1R/GcgR agonist, was shown to reduce blood glycemia, body weight and hepatic steatosis in patients with T2DM. "

05/08/2024 - "In PROXYMO, a 19-week randomized double-blind placebo-controlled trial, the safety and efficacy of cotadutide (600 μg, 300 μg) or placebo were evaluated in 74 participants with biopsy-proven non-cirrhotic MASH with fibrosis. "
01/01/2020 - "Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis."
05/08/2024 - "Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Non-cirrhotic MASH with Fibrosis."
12/01/2023 - "Cotadutide has been shown to improve glycaemic control, body weight, lipids, liver fat, inflammation and fibrosis. "
01/01/2020 - "Significantly, Cotadutide also alleviated fibrosis to a greater extent than Liraglutide or Obeticholic acid (OCA), despite adjusting dose to achieve similar weight loss in 2 preclinical mouse models of NASH. "

03/01/2024 - "The study provides insights into the mechanisms underlying cotadutide's anti-obesity effects and its possible implications for obesity treatment."
12/01/2022 - "Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. "
01/01/2021 - "Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study."
12/01/2023 - "Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes."
01/01/2023 - "These actions rescuing the AMPK and mTOR pathway, improving lipid metabolism, and lessening NAFLD, inflammation, and ER stress in both eWAT and liver of DIO mice indicate cotadutide as a potentially new pharmacological treatment for T2D and associated obesity."

01/01/2021 - "Once-daily cotadutide was effective and well tolerated up to 300 μg in overweight Japanese patients with T2D. "
12/01/2022 - "Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. "
01/01/2021 - "Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study."
12/01/2023 - "Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes."
01/01/2021 - "The effects of cotadutide on hepatic and metabolic parameters were evaluated in participants with overweight/obesity and type 2 diabetes. "